2025 ABAI Continuous Assessment Program - Block Two

The ABAI Continuous Assessment Program serves the need of board certified allergist/immunologists by allowing them to demonstrate their ongoing competence in the field. The program requires allergy/immunology specialists to read and successfully answer three review questions on each of 10 peer­ reviewed articles in the field every six months, along with correctly answering 10 multiple choice question on core topic areas in the specialty.

Accreditation
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of American College of Allergy, Asthma & Immunolgy and  California Society of Allergy, Asthma & Immunology (CSAAI). The American College of Allergy, Asthma & Immunolgy is accredited by the ACCME to provide continuing medical education for physicians.

Designation
The American College of Allergy, Asthma & Immunology (ACAAI) designates this enduring material for a maximum of 6 AMA PRA Category 1 Credit(s)TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Target Audience

Board­ certified allergist/immunologists

Learning Objectives

At the conclusion of this activity, participants should be able to:

1. Outline the major literature published in the specialty during the past 12­-24 months 
2. Demonstrate mastery of core knowledge central to the practice of allergy/immunology

Additional information
Disclosure: 

As required by the Accreditation Council for Continuing Medical Education (ACCME) and in accordance with the American College of Allergy, Asthma & Immunology (ACAAI) policy, all individuals in a position to control or influence the content of an activity must disclose all financial relationships with any ineligible company that have occurred within the past 24 months.

Ineligible companies are those whose primary business is producing, marketing, selling, re-selling, or distributing health care products used by or on patients. The ACCME does not consider providers of clinical service directly to patients to be ineligible companies. Examples of ineligible companies include:

•    Advertising, marketing, or communication firms whose clients are ineligible companies
•    Bio-medical startups that have begun a governmental regulatory approval process
•    Compounding pharmacies that manufacture proprietary compounds
•    Device manufacturers or distributors
•    Diagnostic labs that sell proprietary products
•    Growers, distributors, manufacturers or sellers of medical foods and dietary supplements
•    Manufacturers of health-related wearable products
•    Pharmaceutical companies or distributors
•    Pharmacy benefit managers
•    Reagent manufacturers or sellers

The ACCME does not consider providers of clinical service directly to patients to be commercial interests. For more information, visit www.accme.org. All identified relevant relationships must be mitigated and the educational content thoroughly vetted for fair balance, scientific objectivity, and appropriateness of patient care recommendations. It is required that disclosure of or absence of relevant financial relationships be provided to the learners prior to the start of the activity.

Learners must also be informed when off-label, experimental/investigational uses of drugs or devices are discussed in an educational activity or included in related materials.

Disclosure in no way implies that the information presented is biased or of lesser quality. It is incumbent upon course participants to be aware of these factors in interpreting the program contents and evaluating recommendations. Moreover, expressed views do not necessarily reflect the opinions of the ACAAI. All relevant financial relationships with ineligible companies have been mitigated.

No commerical support was received for this activity.

Course summary
Available credit: 
  • 6.00 AMA PRA Category 1 Credit™
  • 6.00 Attendance
Course opens: 
08/15/2025
Course expires: 
01/15/2026
Rating: 
0

Disclosures
The information disclosed by the faculty and planning committee was reviewed in accordance with the AAAAI and ACAAI Disclosure Policies.
All potential conflicts of interest were mitigated by the planners, faculty and reviewers prior to their participation in the development of this activity.

Planning Committee

Priya Bansal, MD, FACAAI 
Speaker: ALK, AstraZeneca, GSK, Pharming, Regeneron/Sanofi, Roche, Takeda; 
Advisor: ALK, AstraZeneca, CSL Behring, Kalvista, Novartis, Regeneron/Sanofi
Consultant: ALK, AstraZeneca, CSL Behring, Exhale, GSK, Novartis, Roche

Christina E. Ciaccio, MD, FACAAI 
Advisor: Novartis, Genentech
Speaker: Genentech
Researcher: Genentech

Jeffrey G. Demain, MD, FACAAI
Speaker: Blueprint Medicine (speaker)

Hal M. Hoffman, MD
Consultant: Novartis, Akros, 
Advisory Board: Sobi
Research: Takeda, Zomagen, AB2Bio, Zydus

Jay A. Lieberman, MD, FACAAI
Advisory Board: ALK, Aquestiv, Bryn
Research: DBV
Adjudication: Abbvie, Celldex
 
Giselle S. Mosnaim, MD MS, FACAAI
Consultant: Genentech, Novartis, Teva, Aptar
Advisory Board: Chiesi, Sanofi Regeneron, Jasper
Research: GSK, Teva, Genentech, Novartis, Sanofi Regeneron, Aretia, Incyte

Michael R. Nelson, MD PhD, FACAAI
Research: AstraZeneca, Sanofi/Regeneron

Princess U. Ogbogu, MD, FACAAI
Advisory Board: AstraZeneca, GSK
Research: AstraZeneca, Blueprint Medical, DBV, GSK

Jeffrey R. Stokes, MD FAAAAI
Research: Regeneron, Sanofi

Dana V. Wallace, MD, FACAAI
Advisory Board: AbbVie, ARS, Genentech, Grifols
Consultant: Bryn

Julie Wang, MD
Research: DBV Technologies

Faculty
Leonard B. Bacharier, MD
Advisory Board: Aravax, Regeneron
Consultant: AstraZeneca, DBV Technologies, OM Pharma, Sanofi, Vertex, Regeneron, Sanofi

Matthew C. Bell, MD
Speaker: Regeneron
Advisory Board: Sanofi

Luz S. Fonacier, MD, FACAAI
Advisory Board: Abbvie
Consultant: Dermavant, Regeneron
Research: AstraZeneca, Regeneron

Mitchell H. Grayson, MD, FACAAI
Advisory Board: Bayer HealthCare

Pavadee Poowuttikul, MD, FACAAI
Researcher: Respiri, AstraZeneca


The following have no relevant financial relationships with ineligible companies to disclose:

Theresa A. Bingemann, MD, FACAAI, Planning Committee
Denise A. DiPrimio-Kalman, DO, Planning Committee
Theodore M. Freeman, MD, Planning Committee
Mitchell R. Lester, MD, FACAAI, Planning Committee
Anil Nanda, MD, FACAAI, Planning Committee
Miguel A. Park, MD, FACAAI, Planning Committee
Jessica B. Perkins, MD, Planning Committee

Andrew Abreo, MD, Faculty
Karla E. Adams, MD, FACAAI, Faculty
Taha Al-Shaikhly, MBChB, FACAAI, Faculty
Katharine Fast, MD, Faculty
Scott Feldman, MD, PhD, Faculty
Michael H. Land, MD, Faculty
Cecilia Mikita, MD MPH, FACAAI, Faculty
Thanai Pongdee, MD, Faculty 
Constantine K. Saadeh, MD, FACAAI, Faculty
Rebecca Scherzer, MD, Faculty
Elizabeth A. Secord, MD, Faculty
Kelly D. Stone, MD PhD, Faculty
Julie A. Wendt, MD PhD, FACAAI, Faculty
 

Available Credit

  • 6.00 AMA PRA Category 1 Credit™
  • 6.00 Attendance
Please login or create an account to take this course.